Peptides for Men: What the Research Shows, Goal by Goal (2026)
Most guides to peptides for men lump body composition, sex drive, and injury recovery into one shopping list, and the science does not support that shortcut. The compounds men search for sit in separate categories with very different track records: two nudge the body’s own growth hormone, one acts on the brain to affect sexual response, and one is studied almost entirely in animals for tissue repair. Their evidence quality ranges from a formerly approved diagnostic drug to preclinical rodent work.
The Compound Universe Take: The peptides most relevant to men map to three goals, not one. Sermorelin and ipamorelin are growth-hormone secretagogues studied for body composition and recovery, though neither is an approved anti-aging treatment. Bremelanotide (PT-141) reached phase 2 testing for erectile dysfunction in men but is FDA-approved only for women. BPC-157 is a repair peptide with animal data and no approval. Match the compound to the use-case and read each claim against its evidence tier.
New to this topic? Once you know your goal, see the peptides studied for muscle growth for the body-composition lane in more depth.
What “peptides for men” actually covers
A peptide is a short chain of amino acids that signals to cells. That definition stretches from a formerly FDA-approved injectable to gray-market research chemicals, which is why one search term returns such a scattered mix of products.
Sorting the category by goal is the honest first step. Sermorelin and ipamorelin both raise growth hormone, but through different receptors and with different regulatory histories. Bremelanotide acts on the brain, not the bloodstream, so it belongs in the sexual-function bucket rather than the muscle bucket. BPC-157 sits apart again, as a tissue-repair candidate.
One point cuts through the marketing. Only sermorelin was ever FDA-approved, and that was for diagnosing growth hormone deficiency in children, not adult performance. Everything else is off-label, investigational, or research-only.
| Peptide | What it is studied for | Evidence tier |
|---|---|---|
| Sermorelin (GHRH 1-29) | Growth hormone secretion, body composition | Human (approved diagnostic; off-label for adults) |
| Ipamorelin | Growth hormone release, recovery | Animal + early human |
| Bremelanotide (PT-141) | Erectile dysfunction, low desire | Human pilot / phase 2 (men) |
| BPC-157 | Tendon, muscle, and ligament repair | Animal |
The peptides most studied in men, by goal
Sermorelin and ipamorelin: the growth-hormone secretagogues
Sermorelin is a 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH). The FDA approved sermorelin in 1997 under the brand Geref to diagnose and treat growth hormone deficiency in children, but the manufacturer discontinued it around 2008, so today it is available only through compounding pharmacies and off-label [1]. Evidence tier: Human (approved for pediatric diagnosis; adult body-composition use is off-label).
Ipamorelin works from the other side of the same system. Ipamorelin activates the ghrelin receptor to trigger pulsatile growth hormone release, and the original pharmacology paper described it as the first selective growth hormone secretagogue, meaning it raised GH without meaningfully raising cortisol or ACTH [2]. That selectivity is its main talking point. Evidence tier: Animal + early human; not FDA-approved.
The honest limit for both is the gap between mechanism and outcome. Raising growth hormone is well documented; proving that this translates into safe body-composition change in healthy men through controlled trials is not. A review of growth-hormone secretagogues in hypogonadal men frames them as plausible but still-investigational, not established therapy [3]. For the receptor and half-life differences, see how ipamorelin and sermorelin compare.
Bremelanotide (PT-141): the sexual-function peptide
Bremelanotide, also called PT-141, is a melanocortin receptor agonist. Bremelanotide binds melanocortin receptors in the brain rather than acting on blood vessels the way PDE5 inhibitors do, which is why it is studied for desire and central arousal, not just mechanical erection [4].
The male evidence is real but early. In a double-blind, placebo-controlled study, intranasal PT-141 produced a statistically significant erectile response versus placebo in healthy men and men with mild-to-moderate erectile dysfunction, with flushing and nausea the most common side effects [4]. Evidence tier: Human pilot / phase 2 (men).
Here is the catch most listicles blur. The FDA approved bremelanotide (as Vyleesi) in 2019 only for hypoactive sexual desire disorder in premenopausal women, and its developer did not pursue approval for male erectile dysfunction. So for men it remains an investigational, off-label compound.
BPC-157: the tissue-repair peptide
BPC-157 is a pentadecapeptide (15 amino acids) derived from a protein in gastric juice, and it dominates the injury-recovery conversation among men. BPC-157 promotes angiogenesis and collagen synthesis in preclinical models, which is the proposed basis for its tendon, muscle, and ligament effects [5].
The animal data are consistent. In a rat Achilles-tendon detachment model, BPC-157 promoted tendon-to-bone healing and offset the healing damage caused by corticosteroids [5]. Evidence tier: Animal. But almost all of it is animal work, and controlled human trials are not established, so the rodent results are not proof in people.
How they are studied versus how they are sold
The issue is not that these peptides do nothing. It is that a formerly approved drug, two GH secretagogues, and an animal-stage repair peptide get flattened into one “men’s stack.”
Sermorelin has an approval history, but for pediatric diagnosis, not adult physique. Ipamorelin raises growth hormone yet lacks outcome trials in healthy men. Bremelanotide has phase 2 male data but no male approval. BPC-157 is almost entirely preclinical. Reading each claim against its tier keeps expectations grounded.
Read this before the hype: Most peptides marketed to men are not FDA-approved for these uses and are often sold “for research use only,” which means they are not reviewed for safety or purity. This article summarizes published research and regulatory records. It is not medical advice, a dosing guide, or an endorsement of use, and legal status varies by compound and jurisdiction.
| Peptide | Primary mechanism | Evidence maturity | Legal status (US) |
|---|---|---|---|
| Sermorelin | GHRH analog; stimulates pituitary GH | Human (approved diagnostic, discontinued) | Formerly FDA-approved; now compounded / off-label |
| Ipamorelin | Selective ghrelin-receptor (GHS-R) agonist | Animal + early human | Not FDA-approved; research use only |
| Bremelanotide (PT-141) | Melanocortin receptor agonist | Human phase 2 (male ED); phase 3 (female HSDD) | FDA-approved for women only; off-label for men |
| BPC-157 | Angiogenesis; collagen and tissue repair | Animal (preclinical) | Not FDA-approved; regulatory gray zone |
Key takeaways
- Sermorelin was FDA-approved for pediatric growth hormone diagnosis, not adult body composition, and it was later discontinued [1].
- Ipamorelin is a selective growth-hormone secretagogue that raises GH through the ghrelin receptor, but outcome trials in healthy men are lacking [2].
- Bremelanotide (PT-141) reached phase 2 for male erectile dysfunction, yet FDA approval covers only premenopausal women [4].
- BPC-157 shows consistent tendon and tissue-repair effects in animal models, with human trials not established [5].
- Two of these are prescription or formerly approved drugs and two are research compounds, so match each to its goal and evidence tier.
Frequently asked questions
What peptides are most studied for men?
The peptides men search most map to three goals: sermorelin and ipamorelin for growth hormone and body composition, bremelanotide (PT-141) for sexual function, and BPC-157 for tissue repair. Only sermorelin was ever FDA-approved, and that was for pediatric diagnosis.
Are peptides for men FDA-approved?
Mostly no. Sermorelin was approved in 1997 but is discontinued and now compounded off-label, bremelanotide is approved only for women, and ipamorelin and BPC-157 are not FDA-approved.
Do sermorelin and ipamorelin build muscle?
Both raise growth hormone in studies, sermorelin as a GHRH analog and ipamorelin through the ghrelin receptor. Controlled trials showing meaningful, safe muscle or body-composition gains in healthy men are not established.
Does PT-141 work for erectile dysfunction?
A phase 2 study reported a statistically significant erectile response versus placebo in men, and it acts on the brain rather than blood vessels. It is not FDA-approved for men, so it remains investigational for erectile dysfunction.
Is BPC-157 proven to heal injuries?
BPC-157 promotes tendon, muscle, and ligament healing in animal models, mainly rats. Human clinical trials are not established, so it is a research compound rather than a proven treatment.
Are these peptides legal to buy?
Compounds sold “for research use only” are not FDA-approved for personal use and are not reviewed for safety or purity. Legal and compounding status differs by compound and jurisdiction and is changing, so verify current status before relying on any claim.
Interest in peptides for men spans several use-cases, from the growth-hormone secretagogues sermorelin (a GHRH analog) and ipamorelin (a selective ghrelin-receptor agonist) studied for body composition and recovery, to the melanocortin agonist bremelanotide (PT-141) tested in phase 2 for male erectile dysfunction, alongside the pentadecapeptide BPC-157 studied for tendon and ligament repair through angiogenesis and collagen synthesis; Compound Universe tracks each compound against the primary literature and regulatory record so the category is read by evidence tier rather than by marketing.
Because the term peptides for men covers everything from a discontinued growth-hormone diagnostic to an animal-stage repair compound, the useful question is never “which peptide is best for men” but “which goal, and how strong is the evidence.” Two of these compounds carry real regulatory histories and two are research chemicals, so treating them as one stack is where most confusion, and most wasted money, begins.
References
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. PMID 18031173.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822.
- Sinha DK, Balasubramanian A, Tatem AJ, et al. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020. PMC7108996.
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res. 2004. PMID 14963471.
- Krivic A, Anic T, Seiwerth S, Huljev D, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006. PMID 16583442.
Compare next: peptides studied for healing | Compound Universe’s PT-141 research summary | whether peptides are legal